# Lawrence A. Leiter

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/lawrence-a-leiter/

## Facts

| Field | Value |
| --- | --- |
| Citations | 92,495 |
| Field | Diabetes Treatment and Management |
| h-index | 138 |
| i10-index | 481 |
| Last Known Institution | University of Toronto |
| OpenAlex ID | https://openalex.org/A5080414941 |
| ORCID iD | 0000-0002-1040-6229 |
| Works | 869 |

## Researcher papers

Showing 12 of 51.

- [Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes](https://scholariq.org/papers/semaglutide-and-cardiovascular-outcomes-in-patients-with-type-2-diabetes/)
- [Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes](https://scholariq.org/papers/dapagliflozin-and-cardiovascular-outcomes-in-type-2-diabetes/)
- [Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus](https://scholariq.org/papers/saxagliptin-and-cardiovascular-outcomes-in-patients-with-type-2-diabetes/)
- [Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial](https://scholariq.org/papers/dulaglutide-and-cardiovascular-outcomes-in-type-2-diabetes-rewind-a-double-blind/)
- [SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials](https://scholariq.org/papers/sglt2-inhibitors-for-primary-and-secondary-prevention-of-cardiovascular-and/)
- [Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome](https://scholariq.org/papers/effects-of-dalcetrapib-in-patients-with-a-recent-acute-coronary-syndrome/)
- [Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure](https://scholariq.org/papers/sotagliflozin-in-patients-with-diabetes-and-recent-worsening-heart-failure/)
- [Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial](https://scholariq.org/papers/albiglutide-and-cardiovascular-outcomes-in-patients-with-type-2-diabetes-and/)
- [Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol](https://scholariq.org/papers/two-phase-3-trials-of-inclisiran-in-patients-with-elevated-ldl-cholesterol/)
- [Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management](https://scholariq.org/papers/statin-associated-muscle-symptoms-impact-on-statin-therapy-european/)
- [Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease](https://scholariq.org/papers/sotagliflozin-in-patients-with-diabetes-and-chronic-kidney-disease/)
- [2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult](https://scholariq.org/papers/2016-canadian-cardiovascular-society-guidelines-for-the-management-of/)

## Researcher topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Lipoproteins and Cardiovascular Health](https://scholariq.org/topics/lipoproteins-and-cardiovascular-health/)
- [Diabetes, Cardiovascular Risks, and Lipoproteins](https://scholariq.org/topics/diabetes-cardiovascular-risks-and-lipoproteins/)
- [Diabetes Management and Research](https://scholariq.org/topics/diabetes-management-and-research/)
- [Diet and metabolism studies](https://scholariq.org/topics/diet-and-metabolism-studies/)

## Researcher university

- [University of Toronto](https://scholariq.org/institutions/university-of-toronto/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.